Mouse models have long enabled mechanistic studies of intestinal microbiota, mucosal immunity and microbial responses to diet or disease. For developers of live biotherapeutic products (LBPs), however, choosing a model is only the beginning. Differences in gastrointestinal anatomy, microbial ecology and immune physiology can affect administered-strain survival, residence time, efficacy signals and the relevance of a dosing schedule.
Reliable preclinical decisions therefore require a defined model rationale, controlled animal and microbiome variables, quantitative exposure measurements, and prespecified efficacy and safety readouts. Creative Biolabs helps LBP development teams integrate these elements into structured mammalian model studies, so early findings can guide candidate prioritization, follow-up experiments and dose selection without overstating human predictivity.